FDA Panel Recommends Peptides

Participants note the panel's recommendation for BPC-157, TB500, KPV, and Mots-C but doubt it will trigger new trials since that is outside the FDA's role. Some recall prior approvals until 2022, while others question whether final FDA approval will follow the panel vote or affect black/grey market sourcing. Competition from compounding could lower prices, though the FDA's own comments appear unsupportive.

• Panel recommended adding four specific peptides to the 503 bulk list
• Human trials unlikely because they are not the FDA's responsibility
• These substances had earlier approval status until 2022
• FDA historically follows panel votes but final decision remains pending
• Grey-market prices might drop if compounded versions increase competition

Whether the panel's stance reflects sound science or simply acknowledges widespread existing use.

What the FDA will ultimately decide after the panel recommendation.

Nothing here is advice.